This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Horikawa, I. Articles by Barrett, J. C. Search for Related Content PubMed PubMed Citation Articles by Horikawa, I. Articles by Barrett, J. C.

Cloning and Characterization of the Promoter Region of Human Telomerase Reverse Transcriptase Gene

Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709

	ABSTRACT

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Activation of telomerase is one of the rate-limiting steps in human cell immortalization and carcinogenesis. Human telomerase is composed of at least two protein subunits and an RNA component. Regulation of expression of the catalytic subunit, human telomerase reverse transcriptase (hTERT), is suggested as the major determinant of the enzymatic activity. We report here the cloning and characterization of the 5'-regulatory region of the hTERT gene. The highly GC-rich content of the 5' end of the hTERT cDNA spans to the 5'-flanking region and intron 1, making a CpG island. A 1.7-kb DNA fragment encompassing the hTERT gene promoter was placed upstream of the luciferase reporter gene and transiently transfected into human cell lines of fibroblastic and epithelial origins that differed in their expression of the endogenous hTERT gene. Endogenous hTERT-expressing cells, but not nonexpressing cells, showed high levels of luciferase activity, suggesting that the regulation of hTERT gene expression occurs mainly at the transcriptional level. Additional luciferase assays using a series of constructs containing unidirectionally deleted fragments revealed that a 59-bp region (-208 to -150) is required for the maximal promoter activity. The region contains a potential Myc oncoprotein binding site (E-box), and cotransfection of a c-myc expression plasmid markedly enhanced the promoter activity, suggesting a role of the Myc protein in telomerase activation. Identification of the regulatory regions of the hTERT promoter sequence will be essential in understanding the molecular mechanisms of positive and negative regulation of telomerase.

	Introduction

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Telomeres are specialized structures at chromosome ends, which consist of tandemly repeated DNA sequences and associated proteins 1 , 2 . In normal human somatic cells, which show no or little telomerase activity to synthesize new telomeres, the telomeric DNAs progressively shorten with each cell division. Critically short telomeres are suggested to cause irreversible cell growth arrest and cellular senescence 3 , 4 . In contrast, most cancer cells have mechanisms that compensate for telomere shortening, most commonly through the activation of telomerase 5 , allowing them to stably maintain their telomeres and grow indefinitely 3 , 4 , 6 . Thus, activation of telomerase is a rate-limiting step in human carcinogenesis, and telomerase repression in normal human somatic cells can act as a tumor-suppressive mechanism. Three components of the human telomerase enzyme are thus far identified: the RNA component (hTERC), which acts as an intrinsic template for telomeric repeat synthesis 7 ; a telomerase-associated protein (TEP1) with similarity to the Tetrahymena telomerase protein p80 8 , 9 ; and a telomerase catalytic subunit, hTERT,³ which shares several motifs with other known reverse transcriptases 10 , 11 . Recent reconstitution experiments both in vitro and in vivo strongly suggest that hTERT is the major determinant of human telomerase activity 12 , 13 . Concomitant up-regulation or down-regulation of the hTERT mRNA expression and telomerase activity during cell immortalization or differentiation is observed 10 , suggesting that control of the hTERT expression at the mRNA level mainly contributes to the regulation of telomerase enzymatic activity 14 . We found that a putative senescence-inducing gene with a telomerase repressor activity on human chromosome 3p also acts through down-regulation of the hTERT mRNA 15 . How the hTERT mRNA expression is controlled by factors that could play a role in cellular senescence, immortalization, and carcinogenesis (e.g., oncogene products, tumor suppressor gene products, and the telomerase repressor on chromosome 3p) is of great interest. Identification of cis-elements and trans-acting factors that regulate the hTERT gene transcription will help to answer this question. As a first step toward the better understanding of molecular mechanisms of the hTERT gene and telomerase expression, we describe here the cloning and characterization of the promoter region of the hTERT gene.

	Materials and Methods

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Isolation and Sequence Analysis of the hTERT Genomic Clones.
Two independent methods were applied to obtain genomic DNA clones containing the 5'-flanking region of the hTERT gene: PCR-based genomic walking and BAC library screening. For the PCR-based method, we used the Human Genome Walker kit (Clontech Labs, Inc., Palo Alto, CA) according to the supplier’s protocol. The gene-specific primers within the 5'-region of hTERT cDNA were 5'-AGC ACT CGG GCC ACC AGC TCC T-3' (primer GW1) for the initial PCR and 5'-AAC GTG GCC AGC GGC AGC ACC T-3' (primer GW2, Fig. 1 ) for the nested PCR. The use of Advantage-GC Genomic PCR kit (Clontech Labs, Inc.) designed for PCR of highly GC-rich regions was critical to our successful amplification. The final PCR product (1.8 kb in length) was cloned into pCR2.1 vector (Invitrogen Corp., San Diego, CA) via the TA cloning method and sequenced in both strands by the dRhodamine terminator cycle sequencing kit (PE Applied Biosystems, Foster City, CA). The RPCI-11 human BAC library⁴ was screened using a 430-bp hTERT cDNA fragment (nucleotides 18–447 in GenBank AF015950) as a hybridization probe at Research Genetics, Inc. (Huntsville, AL). Two resultant positive BAC clones were sequenced by the BigDye terminator cycle sequencing kit (PE Applied Biosystems) using the primers that were designed based on the sequences from the PCR-based clones described above. A DNA homology search was performed at the National Center for Biotechnology Information using the basic local alignment search tool (BLAST) network service. Potential transcription factor binding sites were predicted by TESS (Transcription Element Search Software⁵ ) search program. A search for the CpG island was carried out using GRAIL (Gene Recognition and Assembly Internet Link, Version 1.3⁶ ). The hTERT promoter sequence shown in Fig. 1 has been submitted to GenBank (accession number AF098956).

View larger version (73K): [in this window] [in a new window]   Fig. 1. Nucleotide sequence of the 5'-flanking region, exon 1, and intron 1 of the hTERT gene. The 5'-flanking region and exon 1 are shown by uppercase letters, and intron 1 is shown by lowercase letters. The major transcription initiation site (+1) and the translation initiation codon (ATG) are doubly underlined. A 1/2 EcoRV site (ATC) at the 5' end, two StuI sites (AGGCCT), two PvuII sites (CAGCTG), and an Eco47III site (AGCGCT) are thinly underlined. The GW2 primer, which was used for the PCR-based genomic walking, is shown by a dashed underline. The 59-bp region responsible for the full promoter activity is highlighted in bold. Potential transcription factor binding sites from the 5'-end of this 59-bp region to the translation initiation codon are shown by thick underlines. The region identical to the HBV integration site in the huH-4 cell line (GenBank X51995) is shown in bold and italic. The HBV genome is inserted adjacent to the position -307 (20) , although the downstream end of the insertion is not precisely determined.

Construction of Luciferase Reporter Gene Constructs.
An 1.7-kb SacI/Eco47III fragment (-1665 to 5 in Fig. 1 ; SacI site was at the multiple cloning sites of the pCR2.1) was ligated to the SacI/SmaI-digested pGL3-Basic vector (Promega Corp., Madison, WI) to allow transcription of firefly luciferase gene under the control of this fragment. The resultant plasmid (pGL3B-TRTP) was digested with SacI and StuI and then divided into two reactions: one was end-polished by T4 DNA polymerase and self-circularized (pBT-SE); and the other was subject to the unidirectional deletions by the Exonuclease III/Mung bean nuclease system (Stratagene Cloning Systems, La Jolla, CA) to make a series of constructs shown in Fig. 3 (pBTdel-X: -X means the nucleotide number in Fig. 1 where the fragment starts). A 251-bp fragment (-211 to 40) was PCR amplified and cloned into the SacI/SmaI-digested pGL3-Basic to produce the plasmid p2XEB. All plasmid DNAs were purified with the QIAfilter plasmid kit (Qiagen, Inc., Chatsworth, CA) and confirmed to have correct sequences by nucleotide sequencing, and their quantity and quality were routinely checked by agarose gel electrophoresis.

View larger version (37K): [in this window] [in a new window]   Fig. 3. Luciferase assay to identify the regions required for the hTERT gene promoter activity. The fragments cloned upstream of the firefly luciferase gene are shown by nucleotide positions that correspond to those in Fig. 1 . For each transfection, the firefly luciferase activity was normalized with the Renilla reniformis luciferase activity by the cotransfected pRL-SV40. The relative activity of each construct is expressed as a ratio to the activity of the pBTdel-279 (CMV-Mj-HEL-1 and SiHa) or the pBTdel-408 (RCC23). The means from at least three independent experiments are shown for each construct; bars, SD.

For luciferase assay, cells (5 to 7.5 x 10⁴) were seeded on 24-well plates, cultured overnight, and transfected with the plasmids described above (1 µg/well) by using the SuperFect transfection reagent (Qiagen). For better comparison among cell lines with different transfection efficiencies (data shown in Table 1 ), the pGL3-Control plasmid (1 µg/well; Promega), which has the firefly luciferase gene under the transcriptional control of SV40 enhancer/promoter, was also transfected into each cell line and used for normalization of the activities shown by the hTERT promoter-luciferase construct. For experiments to identify DNA elements responsible for the hTERT promoter activity in endogenous hTERT mRNA-expressing cells (data shown in Fig. 3 ), the control plasmid, pRL-SV40 (1 ng/well; Promega) containing the Renilla reniformis luciferase gene under the transcriptional control of SV40 enhancer/promoter, was cotransfected with the hTERT promoter-luciferase constructs (1 µg/well, as described above). The level of firefly luciferase activity was normalized to that of Renilla reniformis luciferase activity for each transfection. To investigate a role of c-Myc protein in the hTERT gene transcription (data shown in Fig. 4 ), a human c-myc cDNA expression plasmid, RSVmycSVpA (a kind gift from Dr. Chi V. Dang, Johns Hopkins University, Baltimore, MD), or an empty vector (0.5 µg/well) was cotransfected with the hTERT promoter-luciferase constructs (0.5 µg/well) and the pRL-SV40 (1 ng/well) into the hTERT mRNA-negative SUSM-1 cells. For all experiments, cells were cultured for 45–48 h after transfection, and cell lysates were prepared and examined by using the Dual luciferase reporter assay system (Promega) and the MLX microtiter plate luminometer (Dynex Technologies, Chantilly, VA). All of the data shown in this study were obtained from at least three independent experiments.

View larger version (29K): [in this window] [in a new window]   Fig. 4. Induction of the hTERT gene promoter activity by c-Myc. A human c-myc cDNA expression plasmid or a vector alone was cotransfected with the firefly luciferase construct (pGL3-Basic, pBTdel-408, pBTdel-208, or pBTdel-149) and the pRL-SV40 into the SUSM-1 cells. As in Fig. 3 , the firefly luciferase activity was normalized with the Renilla reniformis luciferase activity. Promoter activity of each combination of plasmids was expressed as fold induction relative to that of combination of the vector alone and the pGL3-Basic. Means from three independent experiments are shown; bars, SD.

	Results

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

View larger version (72K): [in this window] [in a new window]   Fig. 2. RNase protection assay to examine the transcription initiation sites of the hTERT gene. A 460-base RNA probe complementary to the 390-bp sequence of the hTERT gene (from -255 to 135 in Fig. 1 ) was hybridized to the following RNA samples: Lane 1, CMV-Mj-HEL-1; Lane 2, SUSM-1; Lane 3, RCC23; Lane 4, RCC23+3; Lane 5, huH-4; Lane 6, yeast RNA. Left, undigested probe. Size markers were transcribed in vitro from the Century marker template (Ambion). A 135-base major protected fragment and a 390-base fragment specific to huH-4 are indicated by an arrow and an asterisk, respectively. Signals near the bottom of the figure were common to both the hTERT mRNA-positive and -negative cell lines and thus appear to be nonspecific.

To examine the transcriptional activity of the hTERT gene promoter, we first put the 1670-bp fragment (-1665 to 5) upstream of the firefly luciferase gene in the pGL3-Basic vector. The resultant plasmid pGL3B-TRTP was transiently transfected in the endogenous hTERT mRNA-expressing and nonexpressing cells, and the firefly luciferase activity obtained was compared with those from the pGL3-Basic vector alone and the pGL3-Control plasmid, which was used to monitor transfection efficiency (Table 1) . In the hTERT mRNA-positive cells of both fibroblastic (CMV-Mj-HEL-1) and epithelial (SiHa and RCC23) origins, the pGL3B-TRTP showed significant activities, i.e., 6.0–30.9% of the pGL3-Control, or 50–70-fold of the baseline activity of the pGL3-Basic vector. The highest, normalized luciferase activity observed in the CMV-Mj-HEL-1 cells is consistent with the highest expression of endogenous hTERT mRNA in this cell line, as shown in the RNase protection assay (Fig. 2) , making our results convincing. In marked contrast, the pGL3B-TRTP construct resulted in no or little luciferase activity (0.2–1.0% of the pGL3-Control; 1.3–3-fold of the pGL3-Basic) in the hTERT mRNA-negative cells including normal human fibroblasts, SUSM-1, and RCC23+3. These data suggest that the regulation of hTERT gene expression occurs mainly at the transcriptional level, rather than at the posttranscriptional level such as control of mRNA stability. This is also consistent with our finding that treatment of hTERT mRNA-negative cells with cycloheximide to diminish short-lived RNases did not induce the hTERT mRNA expression (data not shown).

We next made a series of luciferase constructs containing unidirectionally deleted fragments from the pGL3B-TRTP and used them for luciferase assay to determine the elements responsible for the hTERT gene promoter activity (Fig. 3) . The plasmid pBTdel-279 (containing -279 to 5) showed the highest promoter activity in the CMV-Mj-HEL-1 and SiHa cells, and pBTdel-408 (containing -408 to 5) was highest in the RCC23 cells. Reduced activities up to 50% of the full promoter activity shown by the constructs containing longer fragments might either reflect the presence of negative regulatory element(s) or be due to the lower transfection efficiency of the larger construct. It is notable that the deletion of the 59-bp region from -208 to -150 resulted in the remarkably decreased promoter activity in all of the cell lines tested, suggesting the presence of a cis-element(s) responsible for the maximal promoter activity within this 59-bp region. Interestingly, the region contains a typical E-box (CACGTG, -187 to -182 in Fig. 1 ), which is known as a potential binding site of the bHLHZ class of transcription factors such as the c-Myc oncoprotein and the upstream stimulatory factor 21 . There is another typical E-box downstream of the major transcription initiation site (22 to 27). The plasmid p2XEB (-211 to 40) containing both of the E-boxes showed similar activity to that of the pBTdel-208 (-208 to 5) or pBTdel-279 (-279 to 5) containing only an upstream E-box, suggesting that the downstream E-box does not have an additive or synergistic effect at least in our transient transfection experiments. As shown in the constructs pBTdel-149 and pBTdel-130, a low but significant transcriptional activity (20–35% of the full promoter activity) was observed, even without either E-box.

To examine a role of the Myc protein in the hTERT gene transcription, a human c-myc cDNA expression plasmid was cotransfected with the hTERT promoter-luciferase constructs in the endogenous hTERT mRNA-negative SUSM-1 cells (Fig. 4) . The c-Myc expression markedly induced the luciferase activity when the constructs containing the upstream E-box (pBTdel-408 and pBTdel-208), but not the pGL3-Basic vector and the pBTdel-149 lacking it, were used. This clearly suggests that the expression of c-Myc protein positively regulates the hTERT gene transcription, probably through the E-box within the 59-bp region identified above. A slight induction observed in the pBTdel-149 might reflect an indirect effect of c-Myc protein by modulating other regulatory factors.

	Discussion

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
The expression of telomerase activity is strongly associated with human cell immortalization and carcinogenesis 3, 4, 5, 6 . Recent studies have suggested that the expression of the telomerase catalytic subunit gene, hTERT, mainly regulates the expression of human telomerase enzymatic activity 10, 11, 12, 13, 14, 15 . Thus, investigation of the molecular mechanisms that regulate the hTERT gene expression could lead to a better understanding of telomerase regulation, cellular senescence and immortalization, and human carcinogenesis. The cloning and characterization of the hTERT gene promoter in this study is an essential step toward this goal. Our luciferase assays with hTERT mRNA-positive versus negative human cell lines of fibroblastic origin (CMV-Mj-HEL-1 versus SUSM-1 and normal human fibroblasts) or epithelial origin (SiHa and RCC23 versus RCC23+3) indicate that the hTERT gene expression is controlled mainly at the transcriptional level. Thus, identification of the cis-elements and trans-acting factors that regulate the hTERT gene transcription is important to understand the regulation of this gene.

By using a series of unidirectionally deleted fragments derived from the hTERT gene promoter, we identified a 59-bp region (-208 to -150 in Fig. 1 ) that is responsible for the maximal promoter activity in human immortal cells of both fibroblastic and epithelial origins. Among the potential transcription factor binding sites within this 59-bp region, a typical E-box (CACGTG, -187 to -182), to which the bHLHZ family of transcription factors bind 21 , is likely to play an important role for the hTERT gene transcription. We showed that the expression of a member of this family, c-Myc oncoprotein, markedly induces the transcriptional activity of the E-box-containing hTERT gene promoter in the endogenous hTERT-negative SUSM-1 cells (Fig. 4) . We also observed a 3–7-fold increase of the promoter activity by the c-Myc expression in the endogenous hTERT-positive cell lines (data not shown). These results suggest an important role of c-Myc in positive regulation of the hTERT gene expression and telomerase activation. This is consistent with the finding by Wang et al. 22 that retroviral expression of c-Myc increases the amount of hTERT mRNA and activates telomerase in human mammary epithelial cells and fibroblasts, although their work did not include transcriptional regulation of the hTERT gene. Considering that activation of c-Myc is a common target of several oncogenic signals, e.g., mutant p53 proteins 23 , viral oncoproteins 24 , and defects in the adenomatous polyposis coli/ß-catenin pathway 25 , an attractive hypothesis is that these oncogenic signals converge on the transactivation of the hTERT gene promoter through c-Myc activation as a part of their oncogenic functions. Involvement of other factors is also possible, including other bHLHZ transcription factors such as upstream stimulatory factor 21 , members of the Ets family of oncoproteins, which are known to cooperate with the bHLHZ proteins 26 , 27 , and the AP-2 family of transcription factors. We are presently investigating direct bindings of these factors, as well as c-Myc protein, to potential binding sites and their functional significance. Although the second typical E-box downstream of the major transcription initiation site appeared to contribute little to the hTERT gene promoter activity in the presence of the upstream E-box (see p2XEB in Fig. 3 ), there is a possibility that the downstream E-box also acts as a positive regulatory element but is functionally redundant with the upstream one. Additional experiments will be needed to address this issue. It should also be noted that the constructs without either E-box (pBTdel-149 and pBTdel-130) still showed low, but significant, promoter activity. Multiple potential binding sites for the Sp1 and MAZ proteins, which function cooperatively at some promoters 28 , 29 , are likely to be responsible for this basal activity of the hTERT gene promoter. Indeed, the Sp1 binding was confirmed in the hTERT mRNA-positive cell lines by a supershift on gel mobility shift assay using a 20-bp probe (-117 to -98, data not shown).

Although in this study we focused our attention on the elements that positively regulate the hTERT gene transcription, the mechanisms involved in the transcriptional repression of the hTERT gene in normal human somatic cells are also of great interest. Although positive regulatory factors, e.g., c-Myc protein, may explain enhanced transcriptional activity, negative regulatory factors that function in telomerase-negative cells may play a role in the transcriptional repression. The hTERT gene promoter sequence and a series of constructs generated in this study may help to identify DNA elements and protein factors that negatively regulate the hTERT gene transcription. It has also been suggested that chromatin structure is a major determinant of gene activity 30 . In this respect, the highly GC-rich content, forming a CpG island, of the hTERT gene promoter is notable. Increased DNA methylation and associated histone deacetylation could turn off the hTERT gene expression by establishing and maintaining an inactive state of chromatin structure.

Finally, we found a genomic rearrangement at the hTERT promoter region in a hepatocellular carcinoma cell line huH-4. The rearrangement probably resulted from the integration of the viral (HBV) genome into the promoter region, which is reminiscent of the activation of some oncogenes by insertion of viral genomes 31 , 32 . Determination of the precise structure of the HBV integration and examination of the transcriptional activity of the rearranged promoter will be needed to clarify functional significance of this rearrangement.

	ACKNOWLEDGMENTS

 
We thank Dr. N. Huh for the huH-4 cell line, Drs. M. Oshimura and H. Tahara for helpful discussions, Drs. R. W. Wiseman and J. I. Risinger for critical reading of the manuscript, and Dr. R. A. Weinberg for the hTERT cDNA.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ I. H. is supported by the Japan Society for the Promotion of Science Research Fellowship for Japanese Biomedical and Behavioral Researchers at NIH.

² To whom requests for reprints should be addressed, at Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, P. O. Box 12233, Research Triangle Park, NC 27709. Phone: (919) 541-2992; Fax: (919) 541-7784; E-mail: barrett{at}niehs.nih.gov

³ The abbreviations used are: hTERT, human telomerase reverse transcriptase; BAC, bacterial artificial chromosome; HBV, hepatitis B virus; bHLHZ, basic helix-loop-helix zipper.

⁴ http://bacpac.med.buffalo.edu.

⁵ http://www.cbil.upenn.edu/tess.

⁶ http://compbio.ornl.gov/Grail-1.3.

Received 10/30/98. Accepted 12/31/98.

	REFERENCES

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 

1. Blackburn E. H. Structure and functions of telomeres. Nature (Lond.), 266: 569-573, 1991.
2. König P., Rhodes D. Recognition of telomeric DNA. Trends Biochem. Sci., 22: 43-47, 1997.[Medline]
3. Chiu C-P., Harley C. B. Replicative senescence and cell immortality: the role of telomeres and telomerase. Proc. Soc. Exp. Biol. Med., 214: 99-106, 1997.[Abstract]
4. Autexier C., Greider C. W. Telomerase and cancer: revisiting the telomere hypothesis. Trends Biochem. Sci., 21: 387-391, 1996.[Medline]
5. Kim N. W., Piatyszek M. A., Prowse K. R., Harley C. B., West M. D., Ho P. L. C., Coviello G. M., Wright W. E., Weinrich S. L., Shay J. W. Specific association of human telomerase activity with immortal cells and cancer. Science (Washington DC), 266: 2011-2015, 1994.[Abstract/Free Full Text]
6. Bodnar A. G., Ouellette M., Frolkis M., Holt S. E., Chiu C-P., Morin G. B., Harley C. B., Shay J. W., Lichtsteiner S., Wright W. E. Extension of life-span by introduction of telomerase into normal human cells. Science (Washington DC), 279: 349-352, 1998.[Abstract/Free Full Text]
7. Feng J., Funk W. D., Wang S-S., Weinrich S. L., Avilion A. A., Chiu C-P., Adams R. R., Chang E., Allsopp R. C., Yu J., Le S., West M. D., Harley C. B., Andrews W. H., Greider C. W., Villeponteau B. The RNA component of human telomerase. Science (Washington DC), 269: 1236-1241, 1995.[Abstract/Free Full Text]
8. Harrington L., McPhail T., Mar V., Zhou W., Oulton R., Amgen EST ProgramBass M. B., Arruda I., Robinson M. O. A mammalian telomerase-associated protein. Science (Washington DC), 275: 973-977, 1997.[Abstract/Free Full Text]
9. Nakayama J., Saito M., Nakamura H., Matsuura A., Ishikawa F. TLP1: a gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family. Cell, 88: 875-884, 1997.[Medline]
10. Meyerson M., Counter C. M., Eaton E. N., Ellisen L. W., Steiner P., Caddle S. D., Ziaugra L., Beijersbergen R. L., Davidoff M. J., Liu Q., Bacchetti S., Haber D. A., Weinberg R. A. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell, 90: 785-795, 1997.[Medline]
11. Nakamura T. M., Morin G. B., Chapman K. B., Weinrich S. L., Andrews W. H., Lingner J., Harley C. B., Cech T. R. Telomerase catalytic subunit homologs from fission yeast and human. Science (Washington DC), 277: 955-959, 1997.[Abstract/Free Full Text]
12. Weinrich S. L., Pruzan R., Ma L., Ouellette M., Tesmer V. M., Holt S. E., Bodnar A. G., Lichtsteiner S., Kim N. W., Trager J. B., Taylor R. D., Carlos R., Andrews W. H., Wright W. E., Shay J. W., Harley C. B., Morin G. B. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat. Genet., 17: 498-502, 1997.[Medline]
13. Nakayama J., Tahara H., Tahara E., Saito M., Ito K., Nakamura H., Nakanishi T., Tahara E., Ide T., Ishikawa F. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat. Genet., 18: 65-68, 1998.[Medline]
14. Ramakrishnan S., Eppenberger U., Mueller H., Shinkai Y., Narayanan R. Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res., 58: 622-625, 1998.[Abstract/Free Full Text]
15. Horikawa I., Oshimura M., Barrett J. C. Repression of the telomerase catalytic subunit by a gene on human chromosome 3 that induces cellular senescence. Mol. Carcinog., 22: 65-72, 1998.[Medline]
16. Hensler P. J., Annab L. A., Barrett J. C., Pereira-Smith O. M. A gene involved in control of human cellular senescence on human chromosome 1q. Mol. Cell. Biol., 14: 2291-2297, 1994.[Abstract/Free Full Text]
17. Uejima H., Shinohara T., Nakayama Y., Kugoh H., Oshimura M. Mapping a novel cellular senescence gene to human chromosome 2q37 by irradiation microcell-mediated chromosome transfer. Mol. Carcinog., 22: 34-45, 1998.[Medline]
18. Nakabayashi K., Ogata T., Fujii M., Tahara H., Ide T., Wadhwa R., Kaul S. C., Mitsui Y., Ayusawa D. Decrease in amplified telomeric sequences and induction of senescence markers by introduction of human chromosome 7 or its segments in SUSM-1. Exp. Cell Res., 235: 345-353, 1997.[Medline]
19. Huh N., Utakoji T. Production of HBs-antigen by two new human hepatoma cell lines and its enhancement by dexamethasone. Gann, 72: 178-179, 1981.[Medline]
20. Kekule A. S., Lauer U., Meyer M., Caselmann W. H., Hofschneider P. H., Koshy R. The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature (Lond.), 343: 457-461, 1990.[Medline]
21. Grandori C., Eisenman R. N. Myc target genes. Trends Biochem. Sci., 22: 177-181, 1997.[Medline]
22. Wang J., Xie L. Y., Allan S., Beach D., Hannon G. J. Myc activates telomerase. Genes Dev., 12: 1769-1774, 1998.[Abstract/Free Full Text]
23. Frazier M. W., He X., Wang J., Gu Z., Cleveland J. L., Zambetti G. P. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol. Cell. Biol., 18: 3735-3743, 1998.[Abstract/Free Full Text]
24. Kinoshita T., Shirasawa H., Shino Y., Moriya H., Desbarats L., Eilers M., Shimizu B. Transactivation of prothymosin and c-myc promoters by human papillomavirus type 16 E6 protein. Virology, 232: 53-61, 1997.[Medline]
25. He T-C., Sparks A. B., Rago C., Hermeking H., Zawel L., da Costa L. T., Morin P. J., Vogelstein B., Kinzler K. W. Identification of c-Myc as a target of the APC pathway. Science (Washington DC), 281: 1509-1512, 1998.[Abstract/Free Full Text]
26. Sieweke M. H., Tekotte H., Jarosch U., Graf T. Cooperative interaction of Ets-1 with USF-1 required for HIV-1 enhancer activity in T cells. EMBO J., 17: 1728-1739, 1998.[Medline]
27. Dang W., Sun X. H., Sen R. ETS-mediated cooperation between basic helix-loop-helix motifs of the immunoglobulin µ heavy chain gene enhancer. Mol. Cell. Biol., 18: 1477-1488, 1998.[Abstract/Free Full Text]
28. Parks C. L., Shenk T. The serotonin 1a receptor gene contains a TATA-less promoter that responds to MAZ and Sp1. J. Biol. Chem., 271: 4417-4430, 1996.[Abstract/Free Full Text]
29. Parks C. L., Shenk T. Activation of the adenovirus major late promoter by transcription factors MAZ and Sp1. J. Virol., 71: 9600-9607, 1997.[Abstract]
30. Razin A. CpG methylation, chromatin structure and gene silencing–a three-way connection. EMBO J., 17: 4905-4908, 1998.[Medline]
31. Nusse R., Theunissen H., Wagenaar E., Rijsewijk F., Gennissen A., Otte A., Schuuring E., Vanooyen A. The Wnt-1 (Int-1) oncogene promoter and its mechanism of activation by insertion of proviral DNA of the mouse mammary tumor virus. Mol. Cell. Biol., 10: 4170-4179, 1990.[Abstract/Free Full Text]
32. Wang J., Zindy F., Chenivesse X., Lamas E., Henglein B., Brechot C. Modification of cyclin A expression by hepatitis B virus DNA integration in a hepatocellular carcinoma. Oncogene, 7: 1653-1656, 1992.[Medline]

This article has been cited by other articles:

				M. Xu, W. Luo, D. J. Elzi, C. Grandori, and D. A. Galloway NFX1 Interacts with mSin3A/Histone Deacetylase To Repress hTERT Transcription in Keratinocytes Mol. Cell. Biol., August 1, 2008; 28(15): 4819 - 4828. [Abstract] [Full Text] [PDF]

				G. J. Bauerschmitz, T. Ranki, L. Kangasniemi, C. Ribacka, M. Eriksson, M. Porten, I. Herrmann, A. Ristimaki, P. Virkkunen, M. Tarkkanen, et al. Tissue-Specific Promoters Active in CD44+CD24-/low Breast Cancer Cells Cancer Res., July 15, 2008; 68(14): 5533 - 5539. [Abstract] [Full Text] [PDF]

				Y.-J. Chen, H. G. Campbell, A. K. Wiles, M. R. Eccles, R. R. Reddel, A. W. Braithwaite, and J. A. Royds PAX8 Regulates Telomerase Reverse Transcriptase and Telomerase RNA Component in Glioma Cancer Res., July 15, 2008; 68(14): 5724 - 5732. [Abstract] [Full Text] [PDF]

				X. Chen, J. Zhang, Y. Fang, C. Zhao, and Y. Zhu Ginsenoside Rg1 Delays Tert-Butyl Hydroperoxide-Induced Premature Senescence in Human WI-38 Diploid Fibroblast Cells J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2008; 63(3): 253 - 264. [Abstract] [Full Text] [PDF]

				M. Bellon and C. Nicot Regulation of Telomerase and Telomeres: Human Tumor Viruses Take Control J Natl Cancer Inst, January 16, 2008; 100(2): 98 - 108. [Abstract] [Full Text] [PDF]

				J. DWYER, H. LI, D. XU, and J.-P. LIU Transcriptional Regulation of Telomerase Activity: Roles of the the Ets Transcription Factor Family Ann. N.Y. Acad. Sci., October 1, 2007; 1114(1): 36 - 47. [Abstract] [Full Text] [PDF]

				L. G. Wooten-Blanks, P. Song, C. E. Senkal, and B. Ogretmen Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1 FASEB J, October 1, 2007; 21(12): 3386 - 3397. [Abstract] [Full Text] [PDF]

				P. Oikonomou, I. Messinis, and A. Tsezou DNA Methylation Is Not Likely to Be Responsible for hTERT Expression in Premalignant Cervical Lesions Experimental Biology and Medicine, July 1, 2007; 232(7): 881 - 886. [Abstract] [Full Text] [PDF]

				T. LEZHAVA and T. JOKHADZE Activation of Pericentromeric and Telomeric Heterochromatin in Cultured Lymphocytes from Old Individuals Ann. N.Y. Acad. Sci., April 1, 2007; 1100(1): 387 - 399. [Abstract] [Full Text] [PDF]

				S. Renaud, D. Loukinov, Z. Abdullaev, I. Guilleret, F. T. Bosman, V. Lobanenkov, and J. Benhattar Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene Nucleic Acids Res., February 28, 2007; 35(4): 1245 - 1256. [Abstract] [Full Text] [PDF]

				G.-S. Shieh, A.-L. Shiau, Y.-T. Yo, P.-R. Lin, C.-C. Chang, T.-S. Tzai, and C.-L. Wu Low-Dose Etoposide Enhances Telomerase-Dependent Adenovirus-Mediated Cytosine Deaminase Gene Therapy through Augmentation of Adenoviral Infection and Transgene Expression in a Syngeneic Bladder Tumor Model. Cancer Res., October 15, 2006; 66(20): 9957 - 9966. [Abstract] [Full Text] [PDF]

				D. Hoffmann and O. Wildner Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy. Mol. Cancer Ther., August 1, 2006; 5(8): 2013 - 2022. [Abstract] [Full Text] [PDF]

				T. Racek, N. Mise, Z. Li, A. Stoll, and B. M. Putzer C-terminal p73 Isoforms Repress Transcriptional Activity of the Human Telomerase Reverse Transcriptase (hTERT) Promoter J. Biol. Chem., December 9, 2005; 280(49): 40402 - 40405. [Abstract] [Full Text] [PDF]

				S. Renaud, D. Loukinov, F. T. Bosman, V. Lobanenkov, and J. Benhattar CTCF binds the proximal exonic region of hTERT and inhibits its transcription Nucleic Acids Res., December 2, 2005; 33(21): 6850 - 6860. [Abstract] [Full Text] [PDF]

				F. Faiola, X. Liu, S. Lo, S. Pan, K. Zhang, E. Lymar, A. Farina, and E. Martinez Dual Regulation of c-Myc by p300 via Acetylation-Dependent Control of Myc Protein Turnover and Coactivation of Myc-Induced Transcription Mol. Cell. Biol., December 1, 2005; 25(23): 10220 - 10234. [Abstract] [Full Text] [PDF]

				M. Quante, S. Heeg, A. von Werder, G. Goessel, C. Fulda, M. Doebele, H. Nakagawa, R. Beijersbergen, H. E. Blum, and O. G. Opitz Differential transcriptional regulation of human telomerase in a cellular model representing important genetic alterations in esophageal squamous carcinogenesis Carcinogenesis, November 1, 2005; 26(11): 1879 - 1889. [Abstract] [Full Text] [PDF]

				M. Takakura, S. Kyo, M. Inoue, W. E. Wright, and J. W. Shay Function of AP-1 in Transcription of the Telomerase Reverse Transcriptase Gene (TERT) in Human and Mouse Cells Mol. Cell. Biol., September 15, 2005; 25(18): 8037 - 8043. [Abstract] [Full Text] [PDF]

				L. G. Wooten and B. Ogretmen Sp1/Sp3-dependent Regulation of Human Telomerase Reverse Transcriptase Promoter Activity by the Bioactive Sphingolipid Ceramide J. Biol. Chem., August 12, 2005; 280(32): 28867 - 28876. [Abstract] [Full Text] [PDF]

				S. Wang and J. Zhu The hTERT Gene Is Embedded in a Nuclease-resistant Chromatin Domain J. Biol. Chem., December 31, 2004; 279(53): 55401 - 55410. [Abstract] [Full Text] [PDF]

				S. C. Verma, S. Borah, and E. S. Robertson Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus Up-Regulates Transcription of Human Telomerase Reverse Transcriptase Promoter through Interaction with Transcription Factor Sp1 J. Virol., October 1, 2004; 78(19): 10348 - 10359. [Abstract] [Full Text] [PDF]

				L. Gewin, H. Myers, T. Kiyono, and D. A. Galloway Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex Genes & Dev., September 15, 2004; 18(18): 2269 - 2282. [Abstract] [Full Text] [PDF]

				B. S. Goueli and R. Janknecht Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf Mol. Cell. Biol., January 1, 2004; 24(1): 25 - 35. [Abstract] [Full Text] [PDF]

				J. Xiong, S. Fan, Q. Meng, L. Schramm, C. Wang, B. Bouzahza, J. Zhou, B. Zafonte, I. D. Goldberg, B. R. Haddad, et al. BRCA1 Inhibition of Telomerase Activity in Cultured Cells Mol. Cell. Biol., December 1, 2003; 23(23): 8668 - 8690. [Abstract] [Full Text] [PDF]

				N. A. Lanson Jr., P. L. Friedlander, P. Schwarzenberger, J. K. Kolls, and G. Wang Replication of an Adenoviral Vector Controlled by the Human Telomerase Reverse Transcriptase Promoter Causes Tumor-Selective Tumor Lysis Cancer Res., November 15, 2003; 63(22): 7936 - 7941. [Abstract] [Full Text] [PDF]

				H. R. McMurray and D. J. McCance Human Papillomavirus Type 16 E6 Activates TERT Gene Transcription through Induction of c-Myc and Release of USF-Mediated Repression J. Virol., September 15, 2003; 77(18): 9852 - 9861. [Abstract] [Full Text] [PDF]

T. Takeda, H. Inaba, M. Yamazaki, S. Kyo, T. Miyamoto, S. Suzuki, T. Ehara, T. Kakizawa, M. Hara, L. J. DeGroot, et al. Tumor-Specific G